Defense Date
7-19-2017
Graduation Date
Fall 1-1-2017
Availability
One-year Embargo
Submission Type
dissertation
Degree Name
PhD
Department
Medicinal Chemistry
School
School of Pharmacy
Committee Chair
Aleem Gangjee
Committee Member
Marc W. Harrold
Committee Member
David J. Lapinsky
Committee Member
Patrick T. Flaherty
Committee Member
Lauren O’Donnell
Committee Member
Rehana Leak
Committee Member
J. Douglas Bricker
Keywords
combination, chemotherapy, pyrimidine, tubulin, antifolate, cancer
Abstract
This dissertation describes the design, synthesis and biological evaluation of monocyclic and bicyclic pyrimidine-base heterocycles as single agents with combination chemotherapy potential having both antiangiogenic effects and cytotoxic effects. This dissertation also describes selective tumor targeting with 5-substituted pyrrolo[2,3-d]pyrimidines analogs with heteroatom bridge substitution as GARFTase inhibitors.
The work in this dissertation is centered on identifying structural features that are necessary for inhibition of tubulin polymerization as well as for inhibition of one or more of the receptor tyrosine kinases (RTKs)- vascular endothelial growth factor receptor-2 (VEGFR2), platelet derived growth factor receptor-β (PDGFRβ) and epidermal growth factor receptor (EGFR) in single entities. Single agents with both antiangiogenic activities as well as cytotoxicity would afford agents that circumvent pharmacokinetic problems of multiple agents, avoid drug-drug interactions, could be used at lower doses to alleviate toxicity, be devoid of overlapping toxicities, and delay or prevent tumor cell resistance.
This work reviews the synthesis of substituted monocyclic pyrimidines as well as pyrrolo[2, 3-d]pyrimidines. This work also reviews the synthesis of multi-transporter (PCFT and FR) selective 5-substituted pyrrolo[2, 3-d]pyrimidines as GARFTase inhibitors circumventing both dose-limiting toxicity and tumor resistance associated with most prescribed antitumor agents like pemetrexed.
Language
English
Recommended Citation
Mohan, R. (2017). Discovery of Pyrimidine-based Heterocycles as Single Agents With Combination Chemotherapy Potential And As Inhibitors Of Purine Nucleotide Biosynthesis For The Treatment of Cancer (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/231
Included in
Heterocyclic Compounds Commons, Organic Chemicals Commons, Other Chemicals and Drugs Commons